KYTHERA Biopharmaceuticals Inc Company News


Old Arcived News About KYTHERA Biopharmaceuticals Inc

  • Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration. [at noodls] - DUBLIN, Ireland and WESTLAKE VILLAGE, Calif., Aug. 05, 2015 (GLOBE NEWSWIRE) -- Allergan plc (NYSE:AGN) and KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced that they have amended and restated ...
  • ALLERGAN PLC. Financials.
  • Allergan reports better-than-expected revenue.
  • Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for Double-Chin. [at noodls] - October 1, 2015 CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 KYBELLA® First FDA-Approved Non-Surgical Injection for Submental Fullness Bolsters Allergan's ...
  • Crude Oil Boosts Stocks as Domestic Inventories Fall.
  • Is Ellie Mae Inc.
  • Kythera Biopharmaceuticals (KYTH) Stock Soaring; Jim Cramer Calls Takeover Deal 'Brilliant'.
  • KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits.
  • KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement.
  • KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders.
  • KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acqu.
  • KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update. [at noodls] - WESTLAKE VILLAGE, Calif., Aug. 06, 2015 (GLOBE NEWSWIRE) -- Westlake Village, Calif., Aug. 6, 2015 - KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the second quarter ...
  • KYTHERA Biopharmaceuticals, Inc. Earnings Q2, 2015.
  • KYTHERA Files IND Application for Male Hair Loss Treatment.
  • KYTHERA Files Regulatory Application for Kybella in EU.
  • KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss. [at noodls] - WESTLAKE VILLAGE, Calif., Sept. 22, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced it has submitted an Investigational New Drug Application (IND) to the U.S. Food ...
  • KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat. [at noodls] - WESTLAKE VILLAGE, Calif., Aug. 18, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) announced today it has submitted a Marketing Authorization Application (MAA) in the European Union ...
  • KYTHERA® Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss. [at noodls] - September 22, 2015 Novel oral treatment could bring new option to large, unsatisfied market Westlake Village, Calif., September 22, 2015 - KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced ...
  • Stock Futures Are Mixed as Investors Await Fed Announcement.
  • Stocks Climb as Fed Meeting Suggests 2015 Hikes.
  • Stocks Turn Lower as Fed Nerves Get the Better of Investors.
  • What to Expect From Allergan Earnings.
  • XBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps.

KYTHERA Biopharmaceuticals Inc Short Company Overview:

KYTHERA Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes prescription products such as submental fat reduction medicine for the aesthetics medicine market. KYTHERA Biopharmaceuticals operates in the United States.